Industry Draws Up Action Plan on Brexit
The global skills shortage in the clinical research sector is being exacerbated in the U.K. by the uncertainty created by Brexit.
The global skills shortage in the clinical research sector is being exacerbated in the U.K. by the uncertainty created by Brexit - the planned exit of the U.K. from the European Union (EU) – which is causing staff to return to their home countries and employers to consider relocating all or part of their organization to non-U.K. EU countries, according to the organizers of this month’s emergency summit about Brexit.
IAOCR, the accrediting organization for the international clinical research industry, held its summit on April 5th. Now it’s producing an initial positioning paper aimed at U.K. politicians, and hopes to meet with the Prime Minister, Theresa May, next month.
In the eyes of most politicians, the U.K. clinical research sector is a “hidden” industry, and the profile of the sector needs to be raised so that the government recognizes clinical research as a sector in its own right and prioritizes it accordingly, noted a statement from IAOCR.
“The U.K. clinical research sector needs to position itself so that it can win clinical trials in the global marketplace,” it stated. “What is the USP (unique selling proposition) for the U.K. clinical trials sector? What can clinical research organizations and the government (individually and collectively) do to provide an attractive environment for clinical trials?”
The organization has the following specific recommendations:
- Improve the regulatory environment by focusing on how to increase speed and efficiency and reduce red tape whilst ensuring patient safety and high quality. Ensuring people working in clinical trials are competent can also reduce errors.
- Provide more tax incentives.
- Provide an environment conducive to patient recruitment, e.g., by boosting awareness of clinical research.
- Improve staff training and allow freedom of movement. Invest in developing staff through apprenticeships, university technical colleges, development of foreign language skills, and ensuring that promotions are based on proof of competence, not length of tenure.
- Reduce costs of clinical research through a competence-based approach that facilitates improved efficiency and productivity, thus bringing new treatments to market quicker.
- Re-introduce the role of a Minister for Life Sciences in the U.K. government structure.
Philip Ward is the European Editor for Applied Clinical Trials
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
